Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brandsma, D.
Right arrow Articles by Voest, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brandsma, D.
Right arrow Articles by Voest, E. E.
Related Collections
Right arrow All Oncology
Right arrow Metastatic tumor
NEUROLOGY 2006;66:243-246
© 2006 American Academy of Neurology
Brief Communications

Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases

D. Brandsma, MD, M.J.B. Taphoorn, MD, PhD, W. de Jager, H. Bonfrer, PhD, A. Algra, PhD, J. C. Reijneveld, MD, PhD, W. Boogerd, MD, PhD, T. Korse, M. M. Verbeek, PhD, G. T. Rijkers, PhD and E. E. Voest, MD, PhD

From the Department of Neurology (D.B., M.J.B.T., A.A., J.C.R.), Laboratory of Medical Oncology of the Department of Medical Oncology (D.B., E.E.V.), and Department of Clinical Epidemiology, Julius Center for Health Sciences and Primary Care (A.A.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Neurology (M.J.B.T.), Medical Center Haaglanden, The Hague, The Netherlands; Department of Pediatric Immunology (W.d.J., G.T.R.), Wilhelmina Children's Hospital, University Medical Center Utrecht/IACOPO Institute for Translational Medicine, Utrecht, The Netherlands; Department of Clinical Chemistry (H.B., K.T.) and Department of Neurology (W.B.), Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; and Department of Neurology (M.M.V.), University Medical Center Nijmegen, Nijmegen, The Netherlands.

Address correspondence and reprint requests to Dr. Brandsma, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands; e-mail: d.brandsma{at}umcutrecht.nl.

Median survival of patients with leptomeningeal metastases (LM) is 4 to 6 months, with a few long-term survivors. Current prognostic factors for survival have limited value. The authors measured the CSF levels of nine inflammatory proteins in 57 patients with LM and determined their prognostic value. High interleukin (IL)-8 CSF levels predicted short-term survival independently. The data indicate that IL-8 CSF levels may serve as a prognosticator in patients with LM, but prospective validation is needed.

Disclosure: The authors report no conflicts of interest.

Received July 5, 2005. Accepted in final form October 7, 2005.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.